HHS, Genentech join forces on medicines to combat influenza, other health security threats

HHS' Office of the Assistant Secretary for Preparedness and Response (ASPR) announced on Monday a strategic partnership with Genentech. The partnership is aimed at developing innovative treatments for national health security threats.

HHS' Office of the Assistant Secretary for Preparedness and Response (ASPR) announced on Monday a strategic partnership with Genentech. The partnership is aimed at developing innovative treatments for national health security threats. The initial focus will be to develop a first-in-class therapeutic for hospitalized influenza patients and a treatment for lung injuries caused by inhaling sulfur mustard gas. "The United States faces a host of national health security threats requiring innovative solutions," said Rick Bright, director of ASPR's Biomedical Advanced Research and Development Authority (BARDA). "Partnership agreements like this one allow flexibility to detect, prevent, or treat diverse illness and injury caused by these threats and at the same time decrease costs and maximize efficiency." Genentech and BARDA will jointly manage and share the cost of developing a portfolio of medicines that meet national health security requirements and have commercial uses. BARDA will also have joint oversight, help assess which medicines to develop, and collaborate on decisions about which products are a part of the joint portfolio.